Baron Daniel Janssen (Honorary Chairman of Solvay, Vice Chairman and Honorary Chairman of the CEO of UCB)
Abbott Laboratories plans to cut its workforce 3% over the next two years. The provision should above all involve Solvay Pharmaceuticals, acquired by the American company for 5.2 billion euros last February. The restructuring, explained the spokesman Scott Stoffel, would affect a total of about 3,000 employees. In particular, Solvay's headquarters in the USA, in Marietta (Georgia) should be closed by the end of 2011, but the job cuts are planned above all in Europe: 500 in Weesp (Holland) and 300 in Hanover (Germany), even if the closure of the plants in question is not foreseen.
Pharmakronos – 23 September 2010 – n. 139 – year 4
Editor's note: Baron Daniel Janssen was the president of the FEB, President of the Administration and President of the members of the commissions of UCB and Solvay, Fortis and Sofina. Daniel Janssen was born in Brussels April 15, 1936, third and youngest son of Charles-Emmanuel Janssen, a liberal deputy in Walloon Brabant, and Maya Boël, daughter of the vice-president of the Senate Boël Pol. Maya Boël's mother, Daniel's grandmother, was Yvonne Solvay. Daniel's brother is Paul Emmanuel Janssen, chairman of the board of directors of the largest Belgian bank. Daniel Janssen is the reference shareholder of Solvay and, through Financier de Tubize, of UCB. André and his brother Eric hold the position of Honorary Directors at UCB. The constellation Solvay – Janssen – Boël, all descendants by blood or marriage, direct and indirect skillfully composed by Ernest Solvay (1838-1922), through an intricate network of cross-shareholdings controls in the fields of chemistry (Solvay, UCB), finance (Sofina Puilaetco), banking (Banca Generale), heavy industry (Mills Gustave Boël), construction (Etex Group, ex Eternit), sale retail (GIB), agri-food (Sipef Interbrew). UCB Italy 20 months ago put all the ISF of "primary care" into mobility.
